Marc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and Secretary
April 18, 2022 at 04:35 pm EDT
Share
On April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity. Mr. Bregman's last day with the Company will be April 29, 2022.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Companyâs segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Companyâs products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
Marc Bregman Notifies Elite Pharmaceuticals, Inc. of His Intent to Leave and Resign from His Position as Chief Financial Officer, Treasurer and Secretary
ELITE PHARMACEUTICALS, INC. 